The 12th JFCR−ISCC

December 3-4, 2007
Keidanren Hall

December 3, 2007 (Monday)

12:00-13:00

(Committee Member Meeting)

Welcome and Introduction

13:30-13:40

Takashi Tsuruo (Cancer Chemotherapy Center, Tokyo)

I Kinase Inhibitors (Part I)

Chairpersons: Joseph Paul Eder (Dana Farber Cancer Inst., Boston)
Takao Yamori (Cancer Chemotherapy Center, Tokyo)

13:40-14:20

Mark Ratain (Univ. of Chicago, Chicago)

Lessons learned from Sorafenib

14:20-14:45

Seiji Naito (Kyushu Univ., Fukuoka)

Sunitinib

14:45-15:25

Jaap Verweij (Erasmus Univ. Medical Center, Rotterdam)

Pazopanib, a novel multitargeted tyrosine kinase inhibitor: Safety and combinability with Lapatinib

15:25-15:35

Discussion

15:35-15:55

Coffee Break

II Kinase Inhibitors (Part II)

Chairpersons: Jaap Verweij (Erasmus Univ. Med. Center, Rotterdam)
Ryuzo Ueda (Nagoya City Univ., Nagoya)

15:55-16:35

Joseph Paul Eder (Dana Farber Cancer Inst., Boston)

The role combinations tyrosine kinase inhibition-more than one pathway, more than one agent?

16:35-17:00

Taira Maekawa (Kyoto Univ., Kyoto)

Bcr-Abl mutations and new agents in the treatment of imatinib-resistant Ph+ leukemias

17:00-17:25

Yoshikazu Sugimoto (Kyoritsu Univ. Pharm., Tokyo)

ABC transporters and signal transduction pathways

17:25-18:05

Elizabeth Eisenhauer (Queen's Univ., Ontario)

Review of phase II experience with targeted drugs:

predictors of success in phase III

18:05-18:15

Discussion

18:15-19:30

Mixer

December 4, 2007 (Tuesday)

III Nuclear Targets and DNA Damage

Chairpersons: Mark Ratain (Univ. of Chicago, Chicago)
Nagahiro Saijo (National Cancer Center Hospital East, Kashiwa)

09:30-09:55

Kimitoshi Kohno (Univ. Occup. Environment. Health, Fukuoka)

Cisplatin resistance and transcription factors

09:55-10:35

Yves G. Pommier (National Cancer Institute, Bethesda)

Topoisomerase inhibitors, camptothecins and beyond

10:35-10:50

Coffee Break

10:50-11:30

Edward A. Sausville (Univ. Maryland, Baltimore)

Aminoflavone: a novel damaging agent

11:30-12:10

Nicola Curtin (Univ. Newcastle upon Tyne, Newcastle)

PARP inhibitors for cancer therapy?

12:10-12:20

Discussion

12:30-13:30

Luncheon Seminars

 

Seminar I (Rm1001(10F))
presented by Taiho Pharmaceutical Co., Ltd.

Chairperson: Yuichi Ando (Nagoya Univ., Nagoya)

Mark Ratain (Univ. of Chicago, Chicago)

Pharmacogenetics of anticancer agents: Distinguishing scientific results from hypothesis

 

Seminar II (Rm1002(10F))
presented by Yakult Honsha, Co., Ltd.

Chairperson: Morito Monden (Osaka Univ., Osaka)

Axel Grothey (Mayo Clinic, Rochester)

The continuum of care in advanced colorectal cancer

IV TGF-β Signaling Inhibitors

Chairpersons: Edward A. Sausville (Univ. Maryland, Baltimore)
Yasuhiro Fujiwara (National Cancer Center Hospital, Tokyo)

13:55-14:40

Kohei Miyazono (Univ. Tokyo, Tokyo)

DDS of TGF-β inhibitor

14:40-14:50

Discussion

14:50-15:20

Coffee Break

VNew Targets & New Drugs (under Clinical Consideration)

Chairpersons: Yves G. Pommier (National Cancer Institute, Bethesda)
Kiyohiko Hatake (Cancer Chemotherapy Center, Tokyo)

15:20-16:00

Axel Grothey (Mayo Clinic, Rochester)

Antiangiogenic therapy in cancer

16:00-16:40

James Christensen (Pfizer Global Research and Development, San Diego)

The role of c-Met in human cancer progression and the discovery and characterization of small molecule inhibitors for therapeutic intervention

16:40-17:05

Yuichi Hashimoto (Univ. Tokyo, Tokyo)

Biological response modifiers derived from thalidomide

17:05-17:15

Discussion

Closing Remark

17:15-17:25

Edward A. Sausville (Univ. Maryland, Baltimore)

Page TOP